Gulrayz Ahmed

ORCID: 0000-0001-6873-9571
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • COVID-19 Clinical Research Studies
  • Lung Cancer Treatments and Mutations
  • Chronic Myeloid Leukemia Treatments
  • Ovarian cancer diagnosis and treatment
  • Multiple Myeloma Research and Treatments
  • SARS-CoV-2 and COVID-19 Research
  • Neutropenia and Cancer Infections
  • Primary Care and Health Outcomes
  • Colorectal Cancer Treatments and Studies
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Obesity, Physical Activity, Diet
  • Venous Thromboembolism Diagnosis and Management
  • Innovations in Medical Education
  • Healthcare Systems and Reforms

Medical College of Wisconsin
2019-2025

Dow University of Health Sciences
2012-2020

Mount Auburn Hospital
2017-2020

Brigham and Women's Hospital
2020

Harvard University
2018-2020

Dana-Farber Cancer Institute
2018

Tufts Medical Center
2017

Right ventricular failure is an underrecognized consequence of COVID-19 pneumonia. Those with severe disease are treated extracorporeal membrane oxygenation (ECMO) but poor outcomes. Concomitant right assist device (RVAD) may be beneficial.A retrospective analysis intensive care unit patients admitted ARDS (Acute Respiratory Distress Syndrome) was performed. Nonintubated patients, those acute kidney injury, and age > 75 were excluded. Patients who underwent RVAD/ECMO support compared managed...

10.1016/j.jss.2021.03.017 article EN other-oa Journal of Surgical Research 2021-03-19

Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area unmet medical need. We report a single-center retrospective analysis 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR) T-cell therapy for their disease, and we describe the safety whole brain radiation (WBRT) as bridging therapy. Six (85.7%) achieved complete response at day 28, 1 patient had progressive disease. The...

10.1182/bloodadvances.2021005292 article EN cc-by-nc-nd Blood Advances 2021-09-22

Background Cytokine release triggered by a hyperactive immune response is thought to contribute severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related failure. Bruton tyrosine kinase (BTK) involved in innate immunity, and BTK inhibitors block cytokine release. We assessed the next-generation inhibitor zanubrutinib SARS-CoV-2–infected patients with distress. Method Cohort 1 had prospective, randomized, double-blind, placebo-controlled design; cohort 2 single-arm design....

10.3389/fimmu.2024.1369619 article EN cc-by Frontiers in Immunology 2025-01-21

Abstract WHIM syndrome is a rare autosomal dominant immunodeficiency disorder and an abbreviation formed from the initial letters of its main clinical presentations: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. It stems mainly mutations where there gain function in chemokine receptor CXCR4, which extensively located on leukocytes, significantly affects balance immune system. Many therapeutic strategies have been widely explored for several years this disorder. Mavorixafor, CXCR4...

10.1093/cei/uxaf014 article EN other-oa Clinical & Experimental Immunology 2025-03-11

Abstract Background Although classical Hodgkin lymphoma (cHL) is highly curable, 20%–30% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food Drug Administration-approved for relapsed/refractory (R/R) cHL. There limited data on the real-world experience PD-1i in cHL it unknown whether fewer selected treated derive benefits similar to those observed published trials. Materials Methods We...

10.1634/theoncologist.2018-0538 article EN The Oncologist 2018-12-19

Weight misperception is the discordance between an individual's actual weight status and perception of his/her weight. It a common problem in youth population as enumerated by many international studies. However data from Pakistan this area deficient. A multi-center cross-sectional survey was carried out undergraduate university students Karachi ages 15–24. Participants were questioned regarding their being thin, normal or fat it compared with Body Mass Index (BMI). Measurements height taken...

10.1186/1471-2458-13-707 article EN cc-by BMC Public Health 2013-08-02

Abstract There is a lack of large comparative study on the outcomes reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood Marrow Transplant Research who received first RIC allo-transplant between 2001 2015 were studied. Patients excluded if they cord blood or identical twin transplant, total body irradiation conditioning,...

10.1182/bloodadvances.2019001266 article EN cc-by-nc-nd Blood Advances 2020-07-14

While most patients with follicular lymphoma (FL) have excellent outcomes frontline chemoimmunotherapy (CIT), a subset of will experience early progression, which is associated poor subsequent outcomes. Novel biomarkers are needed to identify high-risk earlier. We hypothesized that interim positron emission tomography (PET) would predict progression-free survival (PFS) in this population. retrospectively identified 128 grade 1–3A FL who had an PET after 2–4 cycles CIT at 2 academic centers....

10.1097/hs9.0000000000000826 article EN cc-by-nc-nd HemaSphere 2023-01-24

Background: KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients real-world setting, to date, is less established. Objectives: aim our study was review institutional database identify the prevalence actionable genomic alterations KRAS-WT tumors and evaluate patients. Design: We reviewed electronic medical records PDAC advanced disease ( n = 14) who underwent...

10.1177/17588359241253113 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2024-01-01

Abstract Background Thyroidectomy is a common surgical procedure, after which drains are placed routinely. This study aims to assess the benefits of placing postoperative drains, its complications and affects on stay, in thyroid lobectomy. Methodology Randomized Clinical Trial 60 goitre patients undergoing lobectomy was conducted at Civil Hospital Karachi, during July’11-December’11. Patients were randomly assigned into drain non groups. Patient demographics, labs noted. Ultrasound neck...

10.1186/1756-6614-5-9 article EN cc-by Thyroid Research 2012-09-28

Improved biomarkers are required to guide the optimal use of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified using immunoglobulin high-throughput sequencing apheresis (ASC) samples, post-ASCT peripheral blood mononuclear (PBMC), and plasma samples could predict relapse. studied 159 R/R DLBCL who underwent ASCT, whom 98 had an ASC sample 60 surveillance...

10.1182/bloodadvances.2022007706 article EN cc-by-nc-nd Blood Advances 2022-11-18

There is variability in utilization of Comprehensive Genomic Profiling (CGP) most the metastatic solid tumors (MST). We evaluated CGP patterns and its impact on outcomes at an academic tertiary center.Institutional database was reviewed for data adult patients with MST between 01/2012 - 04/2020. Patients were categorized based interval diagnosis; 3 tertiles distribution (T1-earliest to diagnosis, T3-furthest), pre-mets (CGP performed prior diagnosis metastasis). Overall survival (OS)...

10.3389/fonc.2023.1025367 article EN cc-by Frontiers in Oncology 2023-02-14

Abstract Background Severe COVID-19 is uncommon, restricted to 19% of the total population. In response first virus wave (alpha variant SARS-CoV-2), we investigated whether a biomarker indicated severity disease and, in particular, if variable expression angiotensin converting enzyme 2 (ACE2) blood might clarify this difference risk and post COVID -19 conditions (PCC). Methods The IRB-approved study compared patients hospitalized with severe healthy controls. infection was defined requiring...

10.1186/s12879-024-09321-0 article EN cc-by BMC Infectious Diseases 2024-07-03

To examine activity of ibrutinib in steroid-refractory chronic GVHD (SR-cGVHD) after FDA approval, we conducted a multicenter retrospective study. Data were standardly collected (N=270 from 19 centers). Involved organs included skin (75%), eye (61%), mouth (54%), joint/fascia (47%), GI (26%), lung (27%), liver (19%), genital (7%), other (4.4%). NIH severity was mild 5.7%, moderate 42%, severe 53%. 39% had overlap subtype. KPS ≥ 80% 72%. Median prednisone (mg/kg) 0.21 (0-2.27). Ibrutinib...

10.1182/bloodadvances.2024014374 article EN cc-by-nc-nd Blood Advances 2024-10-25

Khorana score (KS) stratifies patients into low, intermediate, and high risk groups for venous thromboembolism (VTE). We examined the generalizability of KS to VTE association with mortality.A retrospective cohort study was conducted at Mount Auburn Hospital, Cambridge, Massachusetts. Patients aged 18 years or older undergoing chemotherapy were included. All evaluated a six-month period. Primary endpoints mortality.Some 277 participants included mean age 63.95 (standard deviation, SD ±...

10.7759/cureus.7883 article EN Cureus 2020-04-29

e16260 Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy holds therapeutic promise based on mechanism action preclinical data. We described characteristics outcomes patients (pts) treated MEK-inh HCQ at our institution. Methods: Ten KRAS-mutated advanced pts were trametinib-HCQ (n = 9) or cobimetinib-HCQ 1)...

10.1200/jco.2022.40.16_suppl.e16260 article EN Journal of Clinical Oncology 2022-06-01
Coming Soon ...